Acadia Pharmaceuticals (ACAD) Current Deferred Revenue (2010 - 2017)

Acadia Pharmaceuticals' Current Deferred Revenue history runs 7 years deep, the most recent figure standing at $4.1 million for Q1 2017.

• In Q1 2017, Current Deferred Revenue changed N/A year-over-year to $4.1 million; the TTM figure through Mar 2017 stood at $4.1 million (changed N/A YoY), while the FY2016 annual figure was $2.6 million, changed N/A from the prior year.
• Current Deferred Revenue was $4.1 million for Q1 2017 at Acadia Pharmaceuticals, up from $2.6 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $4.1 million in Q1 2017 to a low of $15000.0 in Q3 2014.
• Historically, Current Deferred Revenue has averaged $876090.9 across 4 years, with a median of $111000.0 in 2013.
• Biggest YoY gain for Current Deferred Revenue was 69.92% in 2013; the steepest drop was 87.33% in 2013.
• A 4-year view of Current Deferred Revenue shows it stood at $55000.0 in 2013, then tumbled by 72.73% to $15000.0 in 2014, then jumped by 17526.67% to $2.6 million in 2016, then jumped by 56.28% to $4.1 million in 2017.
• The last three Current Deferred Revenue figures came in at $4.1 million (Q1 2017), $2.6 million (Q4 2016), and $1.9 million (Q3 2016), per Business Quant data.